Skip to main content
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in:

18-07-2024 | Pancreatitis | Concise Commentary

Concise Commentary: Does COVID-19 Worsen Severe Pancreaticobiliary Disease?

Author: Marina Kim

Published in: Digestive Diseases and Sciences | Issue 8/2024

Login to get access

Excerpt

During the COVID-19 pandemic, hospitals worldwide faced challenges in managing both elective and urgent procedures, with a shift towards prioritizing critically ill patients for endoscopic procedures such as ERCP for managing pancreaticobiliary disease [1]. Consequently, understanding the impact of SARS-CoV-2 infection on the severity of pancreaticobiliary disease and the risks associated with necessary endoscopic interventions assumed greater importance. …
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Concise Commentary: Does COVID-19 Worsen Severe Pancreaticobiliary Disease?
Author
Marina Kim
Publication date
18-07-2024
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2024
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08554-y

Other articles of this Issue 8/2024

Complications in Patients with Surgically Altered Gastrointestinal Anatomy Undergoing Endoscopic Retrograde Cholangiopancreatography: 15-Year Experience at a Tertiary Care Center in Latin America

Gluten-Free Diet—What’s Good for Celiac Disease Can Be Bad for Metabolism

Patients with Celiac Disease Have High Prevalence of Fatty Liver and Metabolic Syndrome

As the Worm Turns—A Rare Cause of Intestinal Obstruction

Validation of a Machine Learning Algorithm, EVendo, for Predicting Esophageal Varices in Hepatocellular Carcinoma

Impact of COVID-19 Infection on Pancreato-Biliary Diseases Requiring Endoscopic Retrograde Cholangiopancreatography

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s 85th Scientific Sessions.

Read more
Image Credits